Gilead shares rise on HIV combo data

Shares of Gilead Sciences moved up yesterday on the news that its new HIV combo drug dubbed Quad was just as effective as the popular Atripla in a mid-stage trial. Quad combines the approved Truvada therapy with two new agents: elvitegravir and cobicistat. Gilead's stock jumped 4 percent on the news. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.